Recent Updates
Recently added Catalysts
PGEN Neutral Sentiment Score: 55/100

Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25 Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to...

Key Takeaway: Precigen, Inc. is set to announce its full year 2025 financial results and provide business updates on March 25. The announcement will be accessible through a conference call, with details available on the company's website. The press release includes a cautionary statement regarding forward-looking statements, highlighting potential risks and uncertainties related to the company's business strategies and the commercialization of their product, PAPZIMEOS. Stakeholders are advised to review the risk factors outlined in the company's latest Annual Report.

Market Sentiment Analysis

Full Press Release Details

The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call.
Event details can be found on Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations .
Cautionary Statement Regarding Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking statements include, among others, information relating to the Company's business and business plans, the success of efforts to commercialize PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults, the Company's ability to successfully obtain foreign regulatory approvals for PAPZIMEOS, expectations about the safety and efficacy of PAPZIMEOS, the ability of PAPZIMEOS to treat RRP, the Company's future financial and operational results, and the Company's ability to commence clinical studies or complete ongoing clinical studies for the Company's clinical and pre-clinical stage candidates. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.
Investor Contact: Steven M. Harasym Tel: +1 (202) 365-2563 [email protected]
Media Contact: Donelle M. Gregory [email protected]
SOURCE Precigen, Inc.

21 %

Frequently Asked Questions

How can I access the conference call?

Dial 1-800-836-8184 for North America or 1-646-357-8785 internationally.

What is the recommended call-in time before the event?

Participants should dial in 10-15 minutes prior to the scheduled call time.

Where can I find event details for Precigen?

Event information is available at investors.precigen.com/events-presentations.

What are forward-looking statements?

They are projections about future business outcomes, subject to risks.

Who should I contact for investor inquiries?

Contact Steven M. Harasym at +1 (202) 365-2563 or via email.

Last updated: Mar 11, 2026